Shares of pharmaceutical companies fell across Europe and Asia after President Donald Trump said he planned to order a cut in ...

Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...

The president is planning Monday to revive a plan from his first term, which would peg the prices the United States pays for ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE ... Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic ...